Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2003; 29(3): 283-290
DOI: 10.1055/s-2003-40966
DOI: 10.1055/s-2003-40966
Pathogenesis of Increased Risk of Thrombosis in Cancer
Hau C. Kwaan1 , Simrit Parmar2 , Jun Wang2- Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
- 2Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Further Information
Publication History
Publication Date:
30 July 2003 (online)
ABSTRACT
Since the observations of Trousseau, not only has the association of cancer and thrombosis been widely recognized but its pathogenesis is now better understood. Attention to the tumor cell as an important source of procoagulants has also contributed to our knowledge of this problem. Tumor cells express tissue factor (TF) and a cancer procoagulant (CP). TF is dormant in the living cell. However, it is activated during apoptosis of the cell, initiating the coagulation cascade and leading to thrombin generation. Because increased apoptosis occurs during treatment with chemotherapeutic agents, hormones, radiation, and hematopoietic growth factors, as well as when there is rapid tumor proliferation, the thrombosis risk is heightened accordingly. These developments have obvious basic and clinical implications.
KEYWORDS
Thrombosis - cancer - apoptosis - tissue factor - fibrinolysis
REFERENCES
- 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel Dieu de Paris, 2nd ed. Paris: Bailliere 1865 : 654-712
-
2 Billroth T. Lectures on surgical pathology and therapeutics. In: A Handbook for Students and Practitioners (translated) London: The New Sydenham Society
1877-1878
- 3 Kwaan H C, Lo R, McFadzean A JS. Antifibrinolytic activity in primary carcinoma of the liver. Clin Sci . 1959; 18 250-261
- 4 Rickles F R, Levine M N, Edwards R L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev . 1992; 11 237-248
- 5 Falanga A, Barbui T, Rickles F R. et al . Guidelines for clotting studies in cancer patients. Thromb Haemost . 1993; 70 343-350
- 6 Virchow R. Phlogose und Thrombose in Gefäβsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin Virchow R, ed. Frankfurt: Von Meidinger Sohn 1856: 458
- 7 Rickles F R, Levine M N, Dvorak H F. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th ed Philadelphia, PA: Lippincott Williams & Wilkins 2001: 1131-1152
- 8 O'Meara R AQ, Thornes R D. Some properties of the cancer coagulative factor. Ir J Med Sci . 1961; 6 106-112
- 9 O'Meara R AQ. Coagulative properties of cancers. Ir J Med Sci . 1958; 6 474-479
- 10 Dvorak H F, VanDewater L, Bitzer A M. et al . Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res . 1983; 43 4334-4342
- 11 Carmeliet P, Collen D. Tissue factor. Int J Biochem Cell Biol . 1998; 30 661-667
- 12 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest . 1996; 75 281-289
- 13 Edwards R L, Morgan D L, Rickels F R. Animal tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost . 1990; 63 133-138
- 14 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost . 1993; 69 205-213
- 15 Rickles F R, Hair G A, Schmeizl M. et al . All-trans-retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells (Abst). Thromb Haemost . 1993; 69 573
- 16 Wang J, Weiss I, Svoboda K. et al . Thrombogenic role of cells undergoing apoptosis. Br J Haematol . 2001; 115 382-391
- 17 Gale A J, Gordon S G. Update on tumor cell procoagulant factors. Acta Haematol . 2001; 106 25-32
- 18 Gordon S G, Cross B A. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res . 1990; 50 6229-6234
- 19 Kozwich D L, Kramer L C, Mielicki W P. et al . Application of cancer procoagulant as an early detection tumor marker. Cancer . 1994; 74 1367-1376
- 20 Mielicki W P, Tenderenda M, Rutkowski P. et al . Activation of blood coagulation and activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett . 1999; 146 61-66
- 21 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant and tissue factor are differently modulated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood . 1998; 92 143-151
- 22 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid. Leukemia . 1994; 8 156-158
- 23 Koyama T, Hirosawa S, Kawamata N. et al . All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood . 1994; 84 3001-3009
- 24 De Stefano V, Teofili L, Sica S. et al . Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood . 1995; 86 3535-3541
- 25 Nierodzik M LR, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol . 1996; 92 452-457
- 26 Yoshida E, Verrusio E N, Mihara H. et al . Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res . 1994; 54 3300-3304
- 27 Yoshida E, Verrusio E N, Mihara H. et al . Thrombin stimulates expression of the receptor for urokinase-type plasminogen activator in DU-145 prostate cancer cells. Fibrinolysis Proteolysis . 1997; 11 147-154
- 28 Nierodzik M L, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vivo and tumor metastasis in vivo. Cancer Res . 1992; 52 3267-3272
- 29 McNamara C A, Sarembok I J, Gimple L W. Thrombin stimulation of smooth muscle proliferation is mediated by a proteolytic, receptor-mediated mechanism. J Clin Invest . 1992; 91 94-98
- 30 Nierodzik M L, Plotkin A, Kajumo F. et al . Thrombin stimulates tumor-platelet adhesion in vivo. J Clin Invest . 1991; 87 229-236
- 31 Nierodzik M L, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Br J Haematol . 1996; 92 452-457
- 32 Klepfish A, Greco M A, Karpatkin S. Thrombin stimulates melanoma tumor-cells binding to endothelial cells and sub-endothelial matrix. Int J Cancer . 1993; 53 978-982
- 33 Wun T C, Kretzmer K K, Girard T J. et al . Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of the three tandem Kunitz-type inhibitory domains. J Biol Chem . 1988; 263 6001-6004
- 34 Girard T J, Warren L A, Novotny W F. et al . Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature . 1989; 338 518-520
- 35 Rao L V, Rapaport S I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood . 1987; 69 645-651
- 36 Lindahl A K, Ødegaard O R, Sandset P M. et al . Coagulation inhibition and activation in pancreatic cancer. Cancer . 1992; 70 2067-2072
- 37 Lindahl A K, Sandset P M, Abildgaard U. et al . High levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced malignant disease. Acta Chir Scand . 1989; 155 389-393
- 38 Iversen N, Lindahl A-K, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol . 1998; 102 889-895
- 39 Wojtukiewicz M Z, Zacharski L R, Rucinska M. et al . Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost . 1999; 82 1659-1662
- 40 Bajaj M S, Kuppuswamy M N, Saito H. et al . Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitors: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA . 1990; 87 8869-8873
- 41 Ameri A, Kuppuswamy M N, Basu S. et al . Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood . 1992; 79 3219-3226
- 42 Kwaan H C. The plasminogen-plasmin system in malignancy. Cancer Met Rev . 1992; 11 291-311
- 43 Carroll V A, Binder B R. The role of the plasminogen activation system in cancer. Semin Thromb Hemost . 1999; 25 183-197
- 44 Heittiarachchi R JK, Lok J, Prins M H. et al . Undiagnosed malignancy in patients with DVT. Incidence, risk indicators and diagnosis. Cancer . 1998; 83 100-105
- 45 Sørenson H, Mallemakjaer L, Steffen F H. et al . The risk of diagnosis of cancer after primary DVT or PE. N Engl J Med . 1998; 338 1169-1174
- 46 Baron J A, GridleyG, Weiderpass E. et al . Venous thromboembolism and cancer. Lancet . 1998; 351 1077-1080
- 47 Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer. Semin Thromb Haemost . 1999; 25 131-136
- 48 Picioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol . 2001; 106 13-17
- 49 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood . 1992; 79 543-553
- 50 Golomb H, Rowley J D, Vardiman J W. et al . Microgranular acute promyelocytic acute leukemia: a distinct clinical, ultrastructural and cytogenetic entity. Blood . 1980; 55 253-259
- 51 Menell J S, Cesarman G M, Jacovina A T. et al . Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med . 1999; 340 994-1004
- 52 Falanga A, Alessio M G, Donati M B. et al . A new procoagulant in acute leukemia. Blood . 1988; 71 870-875
- 53 Donati M B, Falanga A, Consonni R. et al . Cancer procoagulant in non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost . 1990; 64 11-16
- 54 Bennett B, Booth A, Croll A. et al . The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol . 1989; 71 511-517
- 55 Francis R B, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation. Clinicopathologic correlations. J Lab Clin Med . 1987; 110 541-547
- 56 Stephens R, Alitalo R, Tapiovaara H. et al . Production of an active urokinase by leukemia cells. A novel distinction from cell lines of solid tumors. Leuk Res . 1988; 12 419-422
- 57 Naschitz J E, Yeshurn D, Eldar S. et al . Diagnosis of cancer associated vascular disorders. Cancer . 1996; 77 1759-1767
- 58 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost . 1997; 78 133-136
- 59 Doll D C, Yarbro J W. Vascular toxicity associated with antineoplastic agents. Semin Oncol . 1992; 19 580-596
- 60 von Templehoff F G, Dietrich M, Hommel G. et al . Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol . 1996; 14 2560-2568
- 61 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol . 1991; 9 286-294
- 62 Goodnough L T, Saito H, Manni A. et al . Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer . 1984; 54 1264-1268
- 63 Oberhoff C, Winkler U H, Tauchert A M. et al . Adjuvant CMF chemotherapy in patients with breast cancer-results on blood coagulation and fibrinolysis. Zentralbl Gynäkol . 1997; 119 211-217
- 64 Bertomeu M C, Gallo S, Lauri D. et al . Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Met . 1990; 8 511-518
- 65 Pemberton K D, Melissari E, Kakkar V V. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis . 1993; 4 935-942
- 66 Jankowski J, Ramlau C, Kopczynski Z. et al . Influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J Gynaecol Oncol . 1993; 14(Suppl) 155-158
- 67 Cohen L F, Balow J E, Magrath I T. et al . Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med . 1980; 68 486-491
- 68 Haas M, Ohler L, Watzke H. et al . The spectrum of acute renal failure in tumor lysis syndrome. Nephrol Dial Transplant . 1999; 14 776-779
- 69 Fleming D R, Doukas M A. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma . 1992; 8 315-318
- 70 Jasek A M, Day H G. Acute spontaneous tumor lysis syndrome. Am J Hematol . 1994; 47 129-131